This Article Free Full Text (Free PDF) Free References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Weinberg, M. S Articles by Zappe, D. H Search for Related Content PubMed Articles by Weinberg, M. S Articles by Zappe, D. H Social Bookmarking                         What's this?

The effect of high-dose angiotensin II receptor blockade beyond maximal recommended doses in reducing urinary protein excretion

Division of Nephrology, Roger Williams Medical Center, Boston University School of Medicine Affiliate, Providence, RI 02904 USA, KininMD{at}aol.com

Adam J Weinberg

Division of Nephrology, Roger Williams Medical Center, Boston University School of Medicine Affiliate, Providence, RI 02904 USA

Raymond Cord

Division of Nephrology, Roger Williams Medical Center, Boston University School of Medicine Affiliate, Providence, RI 02904 USA

Dion H Zappe

Division of Nephrology, Roger Williams Medical Center, Boston University School of Medicine Affiliate, Providence, RI 02904 USA

The optimal doses of angiotensin-converting enzyme inhibitors (ACE-I) and/or angiotensin II receptor blockers (ARBs) for maximal reduction in urinary protein excretion are not known. Moreover, beneficial effects from ARBs, such as tissue protection owing to a more complete blockade of the renin-angiotensin-aldosterone system (RAAS), may be independent of blood pressure-lowering by ARBs. In this investigation, we evaluated whether increasing the dose of candesartan cilexetil, in subjects already on the maximally-recommended FDA doses of 32 mg_, would induce a further reduction in 24-hour urinary protein excretion in patients with heavy proteinuria (urinary protein excretion >1.5 g/day; mean 4.4±2 g/day). Ten patients were started on 16 or 32 mg of candesartan cilexetil daily. After 1—2 months of therapy, the dose was titrated upwards to 96 mg. In all subjects, there were further reductions in 24-hour urinary protein excretion when the dose was increased beyond the recommended 32 mg maximal dose. Increasing the dose of candesartan cilexetil to 96 mg was safe, as most subjects showed no changes in serum potassium and, as expected, only a slight increase (0.5—0.7 mg/dl) in serum creatinine. These data warrant further investigation, since some subjects may require higher doses of candesartan to achieve optimal regression of proteinuria.

Key Words: renin-angiotensin system • proteinuria • AT1-receptor antagonists • ACE inhibitors • heavy proteinuria

Journal of Renin-Angiotensin-Aldosterone System, Vol. 2, No. 1 suppl, S196-S198 (2001)
DOI: 10.1177/14703203010020013401


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				E. Burgess, N. Muirhead, P. R. de Cotret, A. Chiu, V. Pichette, S. Tobe, and the SMART (Supra Maximal Atacand Renal Trial) Inve Supramaximal Dose of Candesartan in Proteinuric Renal Disease J. Am. Soc. Nephrol., April 1, 2009; 20(4): 893 - 900. [Abstract] [Full Text] [PDF]

				R. E. Schmieder, A. U. Klingbeil, E. H. Fleischmann, R. Veelken, and C. Delles Additional Antiproteinuric Effect of Ultrahigh Dose Candesartan: A Double-Blind, Randomized, Prospective Study J. Am. Soc. Nephrol., October 1, 2005; 16(10): 3038 - 3045. [Abstract] [Full Text] [PDF]

				N. K. Hollenberg Treatment of the Patient With Diabetes Mellitus and Risk of Nephropathy: What Do We Know, and What Do We Need to Learn? Arch Intern Med, January 26, 2004; 164(2): 125 - 130. [Full Text] [PDF]